A 2-Year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care

Trial Profile

A 2-Year Randomised Parallel Group Trial of Alendronate, Ibandronate and Risedronate for Postmenopausal Osteoporosis in Secondary Care

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Alendronic acid (Primary) ; Ibandronic acid (Primary) ; Risedronic acid (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Pharmacodynamics
  • Acronyms TRIO
  • Most Recent Events

    • 02 Aug 2017 This trial has been completed in UK (on-2013-02-25), according to European Clinical Trials Database
    • 10 Jun 2017 Biomarkers information updated
    • 06 May 2011 Planned End Date changed from 1 Dec 2012 to 1 Dec 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top